The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Under the deal, Quiver will receive an undisclosed advance payment and research support
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
